IP Verse

Methods And Compositions For Adoptive Immunotherapy - EP1827604

The patent EP1827604 was granted to Peter Maccallum Cancer Institute on Nov 20, 2019. The application was originally filed on Dec 12, 2005 under application number EP05815888A. The patent is currently recorded with a legal status of "Revoked".

EP1827604

PETER MACCALLUM CANCER INSTITUTE
Application Number
EP05815888A
Filing Date
Dec 12, 2005
Status
Revoked
Jul 14, 2023
Publication Date
Nov 20, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MATHYS & SQUIREAug 20, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
PATENT BOUTIQUEAug 20, 2020BRISCOEADMISSIBLE
GLAXOSMITHKLINEAug 19, 2020OFARRELLADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONWO0023573
OPPOSITIONWO02077029

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- YEE, C.; J.A. THOMPSON; D. BYRD; S.R. RIDDELL; P. ROCHE; E. CELIS; P.D. GREENBERG, "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells", PROC NATL ACAD SCI USA, (2002), vol. 99, pages 16168 - 16173
EXAMINATION- Pinthus J.H. and Eshhar Z., "The T-body approach: towards cancer immuno-gene therapy", Cancer immune Therapie: current and future strategies, (2002), pages 287 - 298, ISBN 3-527-60079-5
EXAMINATION- BAXEVANIS C N ET AL, "Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, SPRINGER-VERLAG, BERLIN, DE, (20040101), vol. 53, no. 10, doi:10.1007/S00262-004-0523-Y, ISSN 0340-7004, pages 893 - 903, XP009089635
EXAMINATION- MITSUYASU R T ET AL, "Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20000801), vol. 96, no. 3, ISSN 0006-4971, pages 785 - 793, XP002953226
EXAMINATION- Hombach ET AL, "Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.", The Journal of Immunology, (20011201), vol. 167, no. 11, ISSN 0022-1767, pages 6123 - 6131, XP055083123
INTERNATIONAL-SEARCH-REPORT- WALKER R E ET AL, "Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.", BLOOD., (20000715), vol. 96, no. 2, pages 467 - 474, XP003022405
INTERNATIONAL-SEARCH-REPORT- WILLEMSEN R ET AL, "Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.", GENE THERAPY., (200501), vol. 12, no. 2, pages 140 - 146, XP003022404
INTERNATIONAL-SEARCH-REPORT- MOELLER M ET AL, "Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.", BLOOD., (20051101), vol. 106, no. 9, pages 2995 - 3003, XP003022406
INTERNATIONAL-SEARCH-REPORT- MITSUYASU R T ET AL, "Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.", BLOOD., (200008), vol. 96, no. 3, pages 785 - 793, XP002953226
OPPOSITION- ALTENSCHMIDT U, ET AL., "CYTOLYSIS OF TUMOR CELLS EXPRESSING IN THE NEU/ERBB-2, ERBB-3, AND ERBB-4 RECEPTORS BY GENETICALLY TARGETED NAIVE T LYMPHOCYTES", CLINICAL CANCER RESEARCH, US, (19960601), vol. 02, no. 06, ISSN 1078-0432, pages 1001 - 1008, XP001145747
OPPOSITION- ALTENSCHMIDT UWE, KLUNDT E, GRONER B, "Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression", The Journal of Immunology, US, (19971201), vol. 159, no. 11, ISSN 0022-1767, pages 5509 - 5515, XP002533911
OPPOSITION- ALTENSCHMIDT UWE, KLUNDT E, GRONER B, "Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.", The Journal of Immunology, US, (19971201), vol. 159, no. 11, ISSN 0022-1767, pages 5509 - 5515, XP002533911
OPPOSITION- Amadori Alberto, Et Al, "Genetic control of the CD4/CD8 T-cell ratio in humans", Nature Medicine, (19951201), vol. 1, no. 12, pages 1279 - 1283, XP055800006
OPPOSITION- Chang Alfred E, Et Al, "Clinical Observations on Adoptive Immunotherapy with Vaccine-primed T-Lymphocytes Secondarily Sensitized to Tumor in Vitro", Cancer Research, (19930301), vol. 53, pages 1043 - 1050, XP055800292
OPPOSITION- Deeks Steven G, Et Al, "A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy", Molecular Therapy, (20020601), vol. 5, no. 6, pages 788 - 797, XP055800004
OPPOSITION- FINNEY HELENE M , AKBAR ARNE N, LAWSON ALASTAIR D G, "Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRzeta chain.", The Journal of Immunology, US, (20040101), vol. 172, no. 1, ISSN 0022-1767, pages 104 - 113, XP002420497
OPPOSITION- GALLARDO H F ET AL, "Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes.", Blood, US, (19970101), vol. 90, no. 3, ISSN 0006-4971, pages 952 - 957, XP002152873
OPPOSITION- KERSHAW MICHAEL H, ET AL, "Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.", The Journal of Immunology, US, (20040801), vol. 173, no. 3, ISSN 0022-1767, pages 2143 - 2150, XP002533910
OPPOSITION- Marzo Amanda L, Et Al, "Tumor-Specific CD4+ T Cells Have a Major 'Post-Licensing' Role in CTL Mediated Anti-Tumor Immunity", The Journal of Immunology, (20000101), vol. 165, pages 6047 - 6055, XP055800290
OPPOSITION- MORGAN R A,ET AL, "High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.", The Journal of Immunology, US, (20030915), vol. 171, no. 6, ISSN 0022-1767, pages 3287 - 3295, XP002343302
OPPOSITION- Pinthus Jehonathan H, Eshhar Zelig, "14. The T-Body Approach: Towards Cancer Immuno-Gene Therapy", Cancer Immune Therapie: Current and Future Strategies, (20020101), pages 287 - 298, ISBN 978-3-527-30441-7, XP055799999
OPPOSITION- Surman Deborah R, Et Al, "Cutting Edge: CD4+ T Cell Control of CD8+ T Cell Reactivity to a Model Tumor Antigen", The Journal of Immunology, (20000101), vol. 164, pages 562 - 565, XP055800294
OPPOSITION- TIMOTHY J. EBERLEIN, MAURY ROSENSTEIN, and STEVEN A. ROSENBERG, "REGRESSION OF A DISSEMINATED SYNGENEIC SOLID TUMOR BY SYSTEMIC TRANSFER OF LYMPHOID CELLS EXPANDED IN INTERLEUKIN 2", Journal of Experimental Medicine, (19820800), vol. 156, pages 385 - 397, XP055751791
OPPOSITION- WALKER R E ET AL, "Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.", Blood, US, (20000715), vol. 96, no. 2, ISSN 0006-4971, pages 467 - 474, XP003022405
OPPOSITION- Peng Liaomin; Shu Suyu; Krauss John C., "Treatment of Subcutaneous Tumor with Adoptively Transferred T Cells", CELLULAR IMMUNOLOGY, US, (20020525), vol. 178, no. 1, doi:10.1006/cimm.1997.1124, ISSN 0008-8749, pages 24 - 32, XP029582249
OPPOSITION- Baxevanis C N; Papamichai M, "Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes", Cancer Immunology, Berlin/Heidelberg, (20040101), vol. 53, no. 10, doi:10.1007/s00262-004-0523-y, ISSN 0340-7004, pages 893 - 903, XP009089635
OPPOSITION- Baxevanis C N; Papamichai M, "Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes", Cancer Immunology, Immunotherapy,, (20040000), vol. 53, no. 10, pages 893 - 903, XP009089635
OPPOSITION- SHINKAI Y; ET AL, "RAG-2-DEFICIENT MICE LACK MATURE LYMPHOCYTES OWING TO INABILITY TO INITIATE V(D)J REARRANGEMENT", Cell, (19920306), vol. 68, no. 5, pages 855 - 867, XP000604771
OPPOSITION- Seung-Min Shin, Choi Dong-Ki, Jung Keunok, Bae Jeomil, Kim Ji-Sun, Park Seong-Wook, Song Ki-Hoon, Kim Yong-Sung, "Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration", Nature Communications, (20170510), vol. 8, doi:10.1038/ncomms15090, pages 1 - 14, XP055434123
OPPOSITION- BRENTJENS RENIER J ET AL, "Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.", Nature Medicine, New York, (20030301), vol. 9, no. 3, doi:10.1038/nm827, ISSN 1078-8956, pages 279 - 286, XP002389127
OPPOSITION- DUDLEY M E, ROSENBERG S A, "Adoptive-cell-transfer therapy for the treatment of patients with cancer.", Nature Reviews Cancer, London, (20030901), vol. 3, no. 9, doi:10.1038/nrc1167, ISSN 1474-175X, pages 666 - 675, XP002353828
OPPOSITION- SADELAIN M, RIVIERE I, BRENTJENS R, "TARGETING TUMOURS WITH GENETICALLY ENHANCED T LYMPHOCYTES", Nature Reviews Cancer, London, (20030101), vol. 03, no. 01, doi:10.1038/nrc971, ISSN 1474-175X, pages 35 - 45, XP009026020
OPPOSITION- MOELLER et al., "A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells", Cancer Gene Ther., (20040500), vol. 11, pages 371 - 379, XP055751808
OPPOSITION- WILLEMSEN R, ET AL, "Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.", Gene Therapy, GB, (20050101), vol. 12, no. 2, doi:10.1038/sj.gt.3302388, ISSN 0969-7128, pages 140 - 146, XP003022404
OPPOSITION- Nishimura T; Iwakabe K; Sekimoto M; Ohmi Y; Yahata T; Nakui M; Sato T; Habu S; Tashiro H; Sato M; Ohta A, "Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo", Journal of Experimental Medicine,, (19990000), vol. 190, no. 5, pages 617 - 627, XP055034971
OPPOSITION- TENG MICHELE W L; ET AL, "Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes", HUMAN GENE THERAPY,, (20040000), vol. 15, pages 699 - 708, XP002533909
OPPOSITION- TENG MICHELE W L, ET AL, "Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.", HUMAN GENE THERAPY, GB, (20040701), vol. 15, no. 7, doi:10.1089/1043034041361235, ISSN 1043-0342, pages 699 - 708, XP002533909
OPPOSITION- E. Jeffrey Beecham, Shiara Ortiz-Pujols, and Richard P. Junghans, "Dynamics of Tumor Cell Killing by Human T Lymphocytes Armed With an Anti-Carcinoembryonic Antigen Chimeric Immunoglobulin T-Cell Receptor", Journal o f Immunotherapy, (20000000), vol. 23, no. 3, pages 332 - 343, XP055751785
OPPOSITION- E. Jeffrey Beecham, Shiara Ortiz-Pujols, And Richard P. Junghans, "Dynamics of Tumor Cell Killing by Human T Lymphocytes Armed With an Anti-Carcinoembryonic Antigen Chimeric Immunoglobulin T-Cell Receptor", Journal of Immunotherapy, (20000101), vol. 23, no. 3, doi:10.1097/00002371-200005000-00006, pages 332 - 343, XP055751785
OPPOSITION- GYOBU H; ET AL, "Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor", Cancer research,, (20040215), vol. 64, pages 1490 - 1495, XP003020171
OPPOSITION- GYOBU H, ET AL., "Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor", Cancer Research, US, (20040215), vol. 64, doi:10.1158/0008-5472.CAN-03-2780, ISSN 0008-5472, pages 1490 - 1495, XP003020171
OPPOSITION- J. C. Lee, E. Hayman, H. J. Pegram, E. Santos, G. Heller, M. Sadelain, R. Brentjens, "In vivo Inhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy", Cancer research, (20110415), vol. 71, no. 8, doi:10.1158/0008-5472.CAN-10-0552, ISSN 00085472, pages 2871 - 2881, XP055109419
OPPOSITION- MOELLER M; ET AL, "Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection", Blood, (20051101), vol. 106, no. 9, pages 2995 - 3003, XP003022406
OPPOSITION- MOELLER M, ET AL, "Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.", Blood, US, (20051101), vol. 106, no. 9, doi:10.1182/blood-2004-12-4906, ISSN 0006-4971, pages 2995 - 3003, XP003022406
OPPOSITION- MITSUYASU R T, ET AL., "Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects", Blood, US, (20000801), vol. 96, no. 3, ISSN 0006-4971, pages 785 - 793, XP002953226
OPPOSITION- Hombach, Wieczarkowiecz, Marquardt, Heuser, Usai, Pohl, Seliger, Abken, "Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.", The Journal of Immunology, (20011201), vol. 167, no. 11, doi:10.4049/jimmunol.167.11.6123, ISSN 00221767, pages 6123 - 6131, XP055083123
SEARCH- ALTENSCHMIDT U ET AL, "Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 1997, (19971201), vol. 159, no. 11, ISSN 0022-1767, pages 5509 - 5515, XP002533911 [X] 1-17 * the whole document *
SEARCH- ALTENSCHMIDT U ET AL, "CYTOLYSIS OF TUMOR CELLS EXPRESSING IN THE NEU/ERBB-2, ERBB-3, AND ERBB-4 RECEPTORS BY GENETICALLY TARGETED NAIVE T LYMPHOCYTES", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19960601), vol. 2, no. 6, ISSN 1078-0432, pages 1001 - 1008, XP001145747 [X] 1-17 * the whole document *
SEARCH- KERSHAW MICHAEL H ET AL, "Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 2004, (20040801), vol. 173, no. 3, ISSN 0022-1767, pages 2143 - 2150, XP002533910 [X] 1-17 * the whole document *
SEARCH- TENG MICHELE W L ET AL, "Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.", HUMAN GENE THERAPY JUL 2004, (200407), vol. 15, no. 7, ISSN 1043-0342, pages 699 - 708, XP002533909 [X] 1-17 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents